1.
Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clin Endocrinol (Oxf) 2010;72:358–63.CrossrefGoogle Scholar
2.
Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs. Drug Saf 1996;15:53–63.CrossrefPubMedGoogle Scholar
3.
Liaw Y-F. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism: a cohort study. Ann Intern Med. Am Coll Phys 1993;118:424–8.CrossrefGoogle Scholar
4.
Levy M. Propylthiouracil hepatotoxicity. A review and case presentation. Clin Pediatr (Phila) 1993;32:25–9.Google Scholar
5.
Bergman P, Auldist A, Cameron F. Review of the outcome of management of Graves’ disease in children and adolescents. J Paediatr Child Health 2001;37:176–82.CrossrefPubMedGoogle Scholar
6.
Collen RJ, Landaw EM, Kaplan SA, Lippe BM. Remission rates of children and adolescents with thyrotoxicosis treated with antithyroid drugs. Pediatrics 1980;65:550–6.PubMedGoogle Scholar
7.
Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985;60:1019–24.PubMedCrossrefWeb of ScienceGoogle Scholar
8.
Gruñeiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ. Pediatric Graves’ disease: outcome and treatment. J Pediatr Endocrinol Metab 2003;16:1249–55.Google Scholar
9.
Kaguelidou F, Alberti C, Castanet M, Guitteny M-A, Czernichow P, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008;93:3817–26.PubMedWeb of ScienceCrossrefGoogle Scholar
10.
Léger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves’ disease: national long-term cohort study. J Clin Endocrinol Metab 2012;97:110–9.PubMedCrossrefWeb of ScienceGoogle Scholar
11.
Witte J, Goretzki PE, Dotzenrath C, Simon D, Felis P, et al. Surgery for Graves’ disease: total versus subtotal thyroidectomy-results of a prospective randomized trial. World J Surg 2000;24:1303–11.PubMedCrossrefGoogle Scholar
12.
Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, et al. Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab 2000;85:1038–42.PubMedGoogle Scholar
13.
Vitti P, Rago T, Chiovato L, Pallini S, Santini F, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid 1997;7:369–75.CrossrefPubMedGoogle Scholar
14.
Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur J Endocrinol 2002;147:583–9.CrossrefPubMedGoogle Scholar
15.
Eckstein AK, Lax H, Lösch C, Glowacka D, Plicht M, et al. Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 2007;67:607–12.Web of ScienceGoogle Scholar
16.
Rieu M, Raynaud A, Richard A, Laplanche S, Sambor B, et al. Evidence for the effect of antibodies to TSH receptors on the thyroid ultrasonographic volume in patients with Graves’ disease. Clin Endocrinol (Oxf) 1994;41:667–71.CrossrefGoogle Scholar
17.
Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 1997;82:1719–26.PubMedGoogle Scholar
18.
Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, et al. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000;85:3678–82.CrossrefPubMedGoogle Scholar
19.
Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987;64:1241–5.PubMedCrossrefGoogle Scholar
20.
Mussa GC, Corrias A, Silvestro L, Battan E, Mostert M, et al. Factors at onset predictive of lasting remission in pediatric patients with Graves’ disease followed for at least three years. J Pediatr Endocrinol Metab 1999;12:537–41.PubMedCrossrefGoogle Scholar
21.
Buckingham BA. Hyperthyroidism in children. Am J Dis Child. Am Med Assoc 1981;135:112–7.CrossrefGoogle Scholar
22.
Gorton C, Sadeghi-Nejad A, Senior B. Remission in children with hyperthyroidism treated with propylthiouracil. Long-term results. Am J Dis Child 1987;141:1084–6.Google Scholar
23.
Song SM, Youn J-S, Ko JM, Cheon CK, Choi J-H, et al. The natural history and prognostic factors of Graves’ disease in Korean children and adolescents. Korean J Pediatr 2010;53:585–91.CrossrefGoogle Scholar
24.
Léger J, Carel JC. Hyperthyroidism in childhood: causes, when and how to treat. J Clin Res Pediatr Endocrinol 2013;5(Suppl 1):50–6.Google Scholar
25.
Gastaldi R, Poggi E, Mussa A, Weber G, Vigone MC, et al. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. J Pediatr 2014;164:1189–94.e1.PubMedWeb of ScienceCrossrefGoogle Scholar
26.
Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, et al. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 1997;7:755–60.CrossrefPubMedGoogle Scholar
27.
Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics 2008;121:e481–8.Web of ScienceGoogle Scholar
28.
Léger J, Kaguelidou F, Alberti C, Carel JC. Graves’ disease in children. Best Pract Res Clin Endocrinol Metab 2014;28: 233–43.CrossrefPubMedGoogle Scholar
29.
Hampson SE, Skinner TC, Hart J, Storey L, Gage H, et al. Effects of educational and psychosocial interventions for adolescents with diabetes mellitus: a systematic review. Health Technol Assess 2001;5:1–79.PubMedCrossrefGoogle Scholar
30.
Carter S, Taylor D, Levenson R, Britain MP. A question of choice: compliance in medicine taking: a preliminary review. Med Partnership 2003 [cited 2014 Nov 6]. Available at: http://books.google.co.uk/books/about/A_Question_of_Choice.html?id=WXIxMwEACAAJ&pgis=1.
31.
Staples B, Bravender T. Drug compliance in adolescents: assessing and managing modifiable risk factors. Paediatr Drugs 2002;4:503–13.PubMedCrossrefGoogle Scholar
32.
Costello I, Wong IC, Nunn AJ. A literature review to identify interventions to improve the use of medicines in children. Child Care Health Dev 2004;30:647–65.CrossrefGoogle Scholar
33.
Nicholas WC, Fischer RG, Stevenson RA, Bass JD. Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J 1995;88:973–6.CrossrefPubMedGoogle Scholar
34.
Lee JA, Grumbach MM, Clark OH. The optimal treatment for pediatric Graves’ disease is surgery. J Clin Endocrinol Metab 2007;92:801–3.CrossrefPubMedWeb of ScienceGoogle Scholar
35.
Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves’ hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid 1997;7:247–51.PubMedCrossrefGoogle Scholar
36.
Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Reduction in thyroid volume after radioiodine therapy of Graves’ hyperthyroidism: results of a prospective, randomized, multicentre study. Eur J Clin Invest 1996;26:59–63.PubMedCrossrefGoogle Scholar
37.
Rivkees SA. Pediatric Graves’ disease: controversies in management. Horm Res Paediatr 2010;74:305–11.PubMedCrossrefGoogle Scholar
38.
Rivkees SA, Sklar C, Freemark M. Clinical review 99: the management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998;83:3767–76.Google Scholar
39.
Read CH, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab 2004;89:4229–33.CrossrefGoogle Scholar
40.
Levy WJ, Schumacher OP, Gupta M. Treatment of childhood Graves’ disease: a review with emphasis on radioiodine treatment. Cleve Clin J Med 1988;55:373–82.CrossrefPubMedGoogle Scholar
41.
Moll GW, Patel BR. Pediatric Graves’ disease: therapeutic options and experience with radioiodine at the University of Mississippi Medical Center. South Med J 1997;90:1017–22.CrossrefPubMedGoogle Scholar
42.
Turner N, Driver I, Salotti JA, Pearce MS, Cheetham T. Increasing use of radioiodine in young people with thyrotoxicosis in Great Britain. Eur J Endocrinol 2012;167:715–18.Web of ScienceGoogle Scholar
43.
Ma C, Kuang A, Xie J, Liu G. Radioiodine treatment for pediatric Graves’ disease. Cochrane Database Syst Rev 2008;3:CD006294.Web of ScienceGoogle Scholar
44.
Boice JD. Radiation and thyroid cancer: what more can be learned? Acta Oncol 1998;37:321–4.PubMedCrossrefGoogle Scholar
45.
Tucker MA, Jones PH, Boice JD, Robison LL, Stone BJ, et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. Cancer Res 1991;51:2885–8.Google Scholar
46.
Safa AM, Schumacher OP, Rodriguez-Antunez A. Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med 1975;292:167–71.Google Scholar
47.
Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012;380:499–505.Web of ScienceGoogle Scholar
48.
Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, et al. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 2007;109:1972–9.CrossrefPubMedGoogle Scholar
49.
Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, et al. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab. Endocr Soc 1974;38:976–98.CrossrefGoogle Scholar
50.
Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011;21:593–646.Web of ScienceCrossrefGoogle Scholar
Comments (0)